secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0000950170-24-073326
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene Q2 net loss $15.0M; plans EG-70 trial expansion for papillary-only NMIBC
-------------------------------------------------------------------------------

- Net loss of $15.0M ($0.38/share) vs $6.5M ($9.30/share) YoY; operating expenses $17.3M (up from $4.7M).
- Cash and equivalents $264.8M; expects to fund operations into 2027.
- Interim LEGEND cohort data (BCG-unresponsive ~20 patients) expected by end of Sep 2024; BLA mid-2026.
- Plans to expand LEGEND with third cohort (70-100 patients) for papillary-only NMIBC, enrollment Q4 2024.
- Deprioritized cystic fibrosis program EG-i08; Paul Hastings and Wouter Joustra elected to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024073326/0000950170-24-073326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024073326/engn-20240614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-073326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer